| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Diseases | 44 | 2024 | 2083 | 5.780 |
Why?
|
| Renal Insufficiency, Chronic | 24 | 2023 | 2239 | 4.130 |
Why?
|
| Kidney Tubules, Proximal | 55 | 2021 | 382 | 3.980 |
Why?
|
| Hypertension | 64 | 2024 | 8499 | 3.130 |
Why?
|
| Kidney | 78 | 2023 | 7016 | 2.930 |
Why?
|
| Renin-Angiotensin System | 40 | 2022 | 733 | 2.930 |
Why?
|
| Angiotensinogen | 45 | 2021 | 161 | 2.910 |
Why?
|
| Health Promotion | 8 | 2016 | 2204 | 1.630 |
Why?
|
| Thromboplastin | 8 | 2015 | 286 | 1.470 |
Why?
|
| Hematuria | 4 | 2021 | 233 | 1.430 |
Why?
|
| Diabetic Nephropathies | 18 | 2021 | 973 | 1.400 |
Why?
|
| Glucagon-Like Peptides | 2 | 2021 | 153 | 1.350 |
Why?
|
| Angiotensin II | 23 | 2022 | 848 | 1.340 |
Why?
|
| Blood Pressure | 38 | 2024 | 8451 | 1.330 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 5 | 2023 | 325 | 1.300 |
Why?
|
| Antihypertensive Agents | 14 | 2014 | 2016 | 1.270 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 9 | 2014 | 431 | 1.270 |
Why?
|
| Acute Kidney Injury | 14 | 2021 | 1926 | 1.200 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group F-H | 9 | 2024 | 11 | 1.190 |
Why?
|
| Nephrons | 9 | 2023 | 168 | 1.180 |
Why?
|
| Peptidyl-Dipeptidase A | 13 | 2018 | 361 | 1.180 |
Why?
|
| Kidney Transplantation | 23 | 2024 | 4217 | 1.140 |
Why?
|
| Shiga Toxin 1 | 4 | 2015 | 42 | 1.120 |
Why?
|
| Renal Replacement Therapy | 7 | 2016 | 281 | 1.110 |
Why?
|
| Podocytes | 8 | 2024 | 402 | 1.070 |
Why?
|
| Benzazepines | 2 | 2018 | 310 | 1.040 |
Why?
|
| Renin | 23 | 2008 | 635 | 0.990 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2017 | 166 | 0.980 |
Why?
|
| Nephrology | 4 | 2017 | 263 | 0.960 |
Why?
|
| Diabetes Mellitus, Experimental | 19 | 2022 | 1111 | 0.950 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2023 | 12075 | 0.940 |
Why?
|
| Spiro Compounds | 1 | 2023 | 68 | 0.890 |
Why?
|
| Diabetes Mellitus, Type 1 | 10 | 2022 | 3432 | 0.890 |
Why?
|
| Hemolytic-Uremic Syndrome | 6 | 2019 | 106 | 0.880 |
Why?
|
| Kidney Glomerulus | 14 | 2019 | 568 | 0.870 |
Why?
|
| Thiazides | 1 | 2022 | 19 | 0.860 |
Why?
|
| Nephrotic Syndrome | 8 | 2022 | 391 | 0.860 |
Why?
|
| Birth Weight | 7 | 2021 | 2097 | 0.850 |
Why?
|
| Cardiovascular Diseases | 15 | 2024 | 15399 | 0.830 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 6 | 2021 | 241 | 0.810 |
Why?
|
| Graft Rejection | 12 | 2024 | 4426 | 0.780 |
Why?
|
| Hyperaldosteronism | 3 | 2023 | 244 | 0.780 |
Why?
|
| Humans | 221 | 2024 | 758406 | 0.780 |
Why?
|
| Anemia | 4 | 2019 | 1504 | 0.770 |
Why?
|
| Glucosides | 2 | 2016 | 498 | 0.760 |
Why?
|
| Sodium-Glucose Transporter 2 | 4 | 2022 | 89 | 0.760 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 10 | 2014 | 1503 | 0.740 |
Why?
|
| Kidney Tubules | 12 | 2022 | 449 | 0.730 |
Why?
|
| Child | 79 | 2024 | 79818 | 0.730 |
Why?
|
| Lipoproteins | 6 | 2015 | 881 | 0.720 |
Why?
|
| NF-E2-Related Factor 2 | 7 | 2021 | 374 | 0.690 |
Why?
|
| Kidney Function Tests | 7 | 2013 | 677 | 0.680 |
Why?
|
| Overweight | 2 | 2021 | 2411 | 0.680 |
Why?
|
| Diuretics | 1 | 2022 | 610 | 0.670 |
Why?
|
| Benzhydryl Compounds | 2 | 2016 | 900 | 0.660 |
Why?
|
| Urinalysis | 1 | 2021 | 368 | 0.650 |
Why?
|
| Autoantibodies | 2 | 2024 | 2118 | 0.640 |
Why?
|
| Abortion, Criminal | 1 | 2018 | 2 | 0.640 |
Why?
|
| Hypoglycemic Agents | 7 | 2023 | 3069 | 0.640 |
Why?
|
| Urologic Diseases | 1 | 2021 | 248 | 0.630 |
Why?
|
| Proteinuria | 11 | 2009 | 594 | 0.630 |
Why?
|
| Polyuria | 1 | 2018 | 37 | 0.630 |
Why?
|
| Withholding Treatment | 1 | 2022 | 610 | 0.620 |
Why?
|
| PAX2 Transcription Factor | 6 | 2008 | 86 | 0.610 |
Why?
|
| RNA, Messenger | 51 | 2013 | 12759 | 0.610 |
Why?
|
| Albuminuria | 7 | 2020 | 650 | 0.610 |
Why?
|
| Aldosterone | 2 | 2023 | 866 | 0.600 |
Why?
|
| Medicine | 2 | 2024 | 942 | 0.600 |
Why?
|
| Receptor, Angiotensin, Type 2 | 5 | 2022 | 60 | 0.590 |
Why?
|
| Ramipril | 2 | 2009 | 96 | 0.590 |
Why?
|
| Immunologic Factors | 2 | 2024 | 1585 | 0.590 |
Why?
|
| Authorship | 2 | 2019 | 281 | 0.590 |
Why?
|
| Organogenesis | 1 | 2018 | 215 | 0.570 |
Why?
|
| Catalase | 7 | 2014 | 216 | 0.550 |
Why?
|
| Bariatric Surgery | 2 | 2020 | 986 | 0.540 |
Why?
|
| Fetal Development | 3 | 2012 | 766 | 0.540 |
Why?
|
| Infant, Newborn | 25 | 2021 | 26183 | 0.540 |
Why?
|
| Obesity | 8 | 2022 | 12870 | 0.530 |
Why?
|
| Shiga Toxin | 3 | 2024 | 36 | 0.530 |
Why?
|
| Nutritional Status | 2 | 2024 | 1607 | 0.530 |
Why?
|
| Risk Factors | 28 | 2024 | 73809 | 0.530 |
Why?
|
| Membrane Glycoproteins | 8 | 2022 | 3705 | 0.520 |
Why?
|
| Losartan | 12 | 2011 | 265 | 0.520 |
Why?
|
| Multiple Organ Failure | 1 | 2018 | 385 | 0.520 |
Why?
|
| Disease Progression | 18 | 2021 | 13468 | 0.510 |
Why?
|
| Glomerulonephritis | 5 | 2016 | 337 | 0.510 |
Why?
|
| Prehypertension | 1 | 2016 | 63 | 0.510 |
Why?
|
| Patient Participation | 3 | 2023 | 1436 | 0.490 |
Why?
|
| Silicates | 1 | 2014 | 47 | 0.490 |
Why?
|
| Lisinopril | 1 | 2014 | 55 | 0.480 |
Why?
|
| Age of Onset | 6 | 2016 | 3298 | 0.480 |
Why?
|
| Sulfonamides | 2 | 2023 | 1973 | 0.470 |
Why?
|
| Rats | 78 | 2019 | 23679 | 0.470 |
Why?
|
| Insulin Resistance | 5 | 2022 | 3941 | 0.470 |
Why?
|
| Cardiovascular System | 4 | 2021 | 835 | 0.470 |
Why?
|
| Insulin | 17 | 2020 | 6578 | 0.470 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2014 | 28 | 0.470 |
Why?
|
| Receptors, Angiotensin | 5 | 2004 | 141 | 0.470 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 682 | 0.460 |
Why?
|
| Infant, Premature | 4 | 2021 | 2092 | 0.460 |
Why?
|
| Adolescent | 61 | 2024 | 87892 | 0.460 |
Why?
|
| Health Status Disparities | 3 | 2021 | 1831 | 0.460 |
Why?
|
| Imidazoles | 10 | 2022 | 1179 | 0.450 |
Why?
|
| Pediatrics | 4 | 2016 | 3587 | 0.450 |
Why?
|
| Reactive Oxygen Species | 13 | 2018 | 2129 | 0.450 |
Why?
|
| Animals | 145 | 2024 | 167768 | 0.440 |
Why?
|
| Glucose | 18 | 2019 | 4336 | 0.440 |
Why?
|
| Cyclosporine | 4 | 2011 | 777 | 0.440 |
Why?
|
| Child, Preschool | 43 | 2022 | 42062 | 0.440 |
Why?
|
| Apoptosis | 23 | 2019 | 9468 | 0.430 |
Why?
|
| Healthcare Disparities | 5 | 2021 | 3364 | 0.430 |
Why?
|
| Benzoates | 1 | 2014 | 211 | 0.430 |
Why?
|
| Vesico-Ureteral Reflux | 3 | 2014 | 437 | 0.430 |
Why?
|
| Creatinine | 8 | 2022 | 1892 | 0.420 |
Why?
|
| Gene Expression | 23 | 2017 | 7583 | 0.420 |
Why?
|
| Carrier Proteins | 8 | 2022 | 4938 | 0.410 |
Why?
|
| Diabetes Mellitus | 5 | 2024 | 5816 | 0.410 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 787 | 0.410 |
Why?
|
| Blood Transfusion | 1 | 2019 | 1321 | 0.410 |
Why?
|
| Blood Glucose | 12 | 2021 | 6346 | 0.410 |
Why?
|
| Glucocorticoids | 7 | 2022 | 2144 | 0.410 |
Why?
|
| Hyperkalemia | 1 | 2014 | 231 | 0.410 |
Why?
|
| RNA, Ribosomal | 1 | 2013 | 226 | 0.410 |
Why?
|
| Infant Food | 2 | 2012 | 140 | 0.410 |
Why?
|
| Publishing | 1 | 2019 | 833 | 0.400 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 316 | 0.400 |
Why?
|
| Cystatin C | 1 | 2013 | 270 | 0.400 |
Why?
|
| Glomerular Filtration Rate | 15 | 2021 | 2154 | 0.400 |
Why?
|
| Blood Pressure Determination | 6 | 2020 | 634 | 0.390 |
Why?
|
| Fetus | 4 | 2007 | 1859 | 0.390 |
Why?
|
| Gastric Bypass | 1 | 2020 | 817 | 0.390 |
Why?
|
| Age Factors | 14 | 2019 | 18358 | 0.390 |
Why?
|
| Myosin Type I | 1 | 2011 | 23 | 0.390 |
Why?
|
| Congenital Abnormalities | 2 | 2016 | 704 | 0.390 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2014 | 642 | 0.390 |
Why?
|
| Mice, Transgenic | 27 | 2022 | 9518 | 0.380 |
Why?
|
| Caregivers | 2 | 2020 | 2225 | 0.380 |
Why?
|
| Thermogenesis | 1 | 2015 | 468 | 0.370 |
Why?
|
| Preventive Health Services | 1 | 2016 | 570 | 0.370 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 3801 | 0.370 |
Why?
|
| Epidemics | 4 | 2023 | 512 | 0.370 |
Why?
|
| Hemoglobins | 2 | 2007 | 1519 | 0.370 |
Why?
|
| Language | 1 | 2020 | 1532 | 0.360 |
Why?
|
| Food Contamination | 2 | 2009 | 192 | 0.360 |
Why?
|
| Oxidative Stress | 9 | 2019 | 3099 | 0.360 |
Why?
|
| Infant Formula | 2 | 2009 | 193 | 0.360 |
Why?
|
| Rare Diseases | 2 | 2017 | 619 | 0.350 |
Why?
|
| Triazines | 2 | 2009 | 310 | 0.350 |
Why?
|
| Sirolimus | 2 | 2011 | 1533 | 0.340 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2012 | 293 | 0.340 |
Why?
|
| Hypertension, Renal | 6 | 2009 | 135 | 0.340 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 3754 | 0.340 |
Why?
|
| Self-Help Groups | 1 | 2011 | 188 | 0.340 |
Why?
|
| Metabolomics | 2 | 2021 | 1629 | 0.330 |
Why?
|
| Gene Expression Regulation | 22 | 2019 | 11892 | 0.330 |
Why?
|
| Benzimidazoles | 1 | 2014 | 855 | 0.330 |
Why?
|
| HIV Seropositivity | 1 | 2015 | 960 | 0.330 |
Why?
|
| Endothelial Cells | 6 | 2024 | 3533 | 0.330 |
Why?
|
| Glucose Intolerance | 2 | 2019 | 575 | 0.330 |
Why?
|
| Immunosuppressive Agents | 6 | 2024 | 4158 | 0.320 |
Why?
|
| Urinary Tract Infections | 4 | 2014 | 812 | 0.320 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2011 | 203 | 0.320 |
Why?
|
| Prenatal Exposure Delayed Effects | 5 | 2024 | 2496 | 0.310 |
Why?
|
| Peer Review, Research | 2 | 2019 | 340 | 0.310 |
Why?
|
| Adipocytes | 1 | 2015 | 1177 | 0.310 |
Why?
|
| Adult | 43 | 2022 | 219935 | 0.300 |
Why?
|
| Mice | 60 | 2024 | 81101 | 0.300 |
Why?
|
| Membrane Proteins | 3 | 2024 | 7843 | 0.300 |
Why?
|
| Fibrosis | 7 | 2018 | 2038 | 0.300 |
Why?
|
| Antidepressive Agents | 3 | 2024 | 2889 | 0.300 |
Why?
|
| Health Services Accessibility | 4 | 2024 | 5404 | 0.300 |
Why?
|
| Fumarates | 1 | 2008 | 131 | 0.290 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2021 | 849 | 0.290 |
Why?
|
| Polymers | 1 | 2014 | 1616 | 0.290 |
Why?
|
| Cell Line, Transformed | 16 | 2012 | 869 | 0.290 |
Why?
|
| Biological Products | 1 | 2016 | 906 | 0.290 |
Why?
|
| Organ Size | 4 | 2009 | 2252 | 0.280 |
Why?
|
| Tetrazoles | 4 | 2011 | 899 | 0.280 |
Why?
|
| Up-Regulation | 13 | 2021 | 4113 | 0.280 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2015 | 4342 | 0.280 |
Why?
|
| Osteoporosis | 1 | 2016 | 1598 | 0.280 |
Why?
|
| Down-Regulation | 6 | 2024 | 2904 | 0.280 |
Why?
|
| Male | 107 | 2024 | 358747 | 0.270 |
Why?
|
| Urinary Bladder | 3 | 2021 | 1166 | 0.270 |
Why?
|
| Female | 83 | 2024 | 390323 | 0.260 |
Why?
|
| Infant | 28 | 2021 | 36055 | 0.260 |
Why?
|
| Epithelial Cells | 9 | 2022 | 3664 | 0.260 |
Why?
|
| Gestational Age | 2 | 2021 | 3565 | 0.260 |
Why?
|
| Immunoglobulin G | 2 | 2017 | 4540 | 0.250 |
Why?
|
| Amides | 1 | 2008 | 447 | 0.250 |
Why?
|
| Tissue Donors | 2 | 2015 | 2311 | 0.250 |
Why?
|
| Infant, Low Birth Weight | 3 | 2021 | 859 | 0.250 |
Why?
|
| Pregnancy | 16 | 2024 | 29742 | 0.250 |
Why?
|
| Cystinosis | 3 | 2005 | 26 | 0.250 |
Why?
|
| Heme Oxygenase-1 | 6 | 2016 | 363 | 0.240 |
Why?
|
| Ureter | 1 | 2007 | 375 | 0.240 |
Why?
|
| Ureteral Obstruction | 2 | 2003 | 292 | 0.240 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2007 | 406 | 0.230 |
Why?
|
| Morphogenesis | 2 | 2008 | 740 | 0.230 |
Why?
|
| Sodium Chloride | 4 | 2021 | 588 | 0.230 |
Why?
|
| Cells, Cultured | 25 | 2021 | 18940 | 0.230 |
Why?
|
| Aquaporin 1 | 2 | 2016 | 57 | 0.230 |
Why?
|
| Critical Illness | 1 | 2016 | 2703 | 0.220 |
Why?
|
| Weight Gain | 1 | 2014 | 2346 | 0.220 |
Why?
|
| Embryonic and Fetal Development | 1 | 2004 | 420 | 0.220 |
Why?
|
| Health Policy | 1 | 2016 | 2677 | 0.220 |
Why?
|
| Autocrine Communication | 2 | 2007 | 169 | 0.220 |
Why?
|
| Research Support as Topic | 2 | 2007 | 697 | 0.220 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 2 | 2017 | 15 | 0.210 |
Why?
|
| Erythropoiesis | 1 | 2007 | 682 | 0.210 |
Why?
|
| Transforming Growth Factor beta1 | 7 | 2019 | 607 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 2872 | 0.210 |
Why?
|
| Depressive Disorder | 3 | 2024 | 3727 | 0.210 |
Why?
|
| Congresses as Topic | 3 | 2017 | 799 | 0.210 |
Why?
|
| Law Enforcement | 1 | 2024 | 112 | 0.210 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 278 | 0.210 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 78 | 0.210 |
Why?
|
| Hypoxia-Inducible Factor 1 | 4 | 2007 | 192 | 0.210 |
Why?
|
| Disease Models, Animal | 13 | 2021 | 18119 | 0.200 |
Why?
|
| Prognosis | 11 | 2019 | 29557 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 5 | 2006 | 1958 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2022 | 1593 | 0.200 |
Why?
|
| Shiga Toxin 2 | 2 | 2019 | 21 | 0.200 |
Why?
|
| Vasoconstrictor Agents | 2 | 2004 | 651 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2007 | 989 | 0.190 |
Why?
|
| Angiotensin I | 3 | 2018 | 56 | 0.190 |
Why?
|
| Proteins | 3 | 2015 | 6026 | 0.190 |
Why?
|
| Human Rights | 1 | 2024 | 309 | 0.190 |
Why?
|
| Cell Line | 22 | 2021 | 15591 | 0.190 |
Why?
|
| DNA-Binding Proteins | 5 | 2004 | 9574 | 0.190 |
Why?
|
| Cystoscopy | 1 | 2021 | 133 | 0.190 |
Why?
|
| Diet Therapy | 1 | 2002 | 150 | 0.180 |
Why?
|
| Living Donors | 1 | 2005 | 638 | 0.180 |
Why?
|
| Sirtuin 1 | 2 | 2024 | 246 | 0.180 |
Why?
|
| Obesity, Morbid | 1 | 2011 | 1277 | 0.180 |
Why?
|
| Urinary Bladder Diseases | 1 | 2021 | 169 | 0.180 |
Why?
|
| Steroids | 2 | 2022 | 926 | 0.180 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2003 | 791 | 0.180 |
Why?
|
| Stroke | 2 | 2021 | 9694 | 0.170 |
Why?
|
| Glycosuria | 1 | 2019 | 44 | 0.170 |
Why?
|
| Immune System | 1 | 2005 | 796 | 0.170 |
Why?
|
| Transcription Factors | 8 | 2006 | 12094 | 0.170 |
Why?
|
| World Health Organization | 2 | 2016 | 1312 | 0.170 |
Why?
|
| Feeding Behavior | 1 | 2012 | 3184 | 0.170 |
Why?
|
| Rats, Wistar | 11 | 2009 | 1844 | 0.170 |
Why?
|
| Naphthyridines | 1 | 2020 | 138 | 0.170 |
Why?
|
| Confidentiality | 1 | 2004 | 610 | 0.170 |
Why?
|
| HLA Antigens | 3 | 2005 | 1368 | 0.170 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2022 | 269 | 0.170 |
Why?
|
| Animals, Newborn | 4 | 2008 | 2672 | 0.170 |
Why?
|
| Health Education | 2 | 2016 | 1049 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2007 | 3602 | 0.160 |
Why?
|
| Diabetes, Gestational | 3 | 2015 | 1241 | 0.160 |
Why?
|
| Calcium, Dietary | 1 | 2002 | 529 | 0.160 |
Why?
|
| Blotting, Western | 9 | 2021 | 5031 | 0.160 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 368 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2020 | 8544 | 0.160 |
Why?
|
| Mannose-Binding Lectin | 1 | 2019 | 146 | 0.160 |
Why?
|
| Heme Oxygenase (Decyclizing) | 4 | 2003 | 167 | 0.160 |
Why?
|
| Molecular Biology | 4 | 2006 | 580 | 0.150 |
Why?
|
| Diabetes Insipidus | 1 | 2018 | 144 | 0.150 |
Why?
|
| Enzyme Inhibitors | 9 | 2011 | 3709 | 0.150 |
Why?
|
| Systole | 2 | 2019 | 936 | 0.150 |
Why?
|
| Fetofetal Transfusion | 1 | 1999 | 112 | 0.150 |
Why?
|
| Informed Consent | 1 | 2004 | 1003 | 0.140 |
Why?
|
| Kidney Calculi | 1 | 2002 | 468 | 0.140 |
Why?
|
| Simian virus 40 | 4 | 2003 | 291 | 0.140 |
Why?
|
| Reference Values | 5 | 2014 | 4919 | 0.140 |
Why?
|
| Signal Transduction | 16 | 2017 | 23342 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 5 | 2007 | 2457 | 0.140 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 584 | 0.140 |
Why?
|
| Mass Screening | 3 | 2024 | 5427 | 0.140 |
Why?
|
| Hyperglycemia | 3 | 2021 | 1368 | 0.140 |
Why?
|
| Receptor, Angiotensin, Type 1 | 3 | 2007 | 148 | 0.140 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 664 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 7378 | 0.140 |
Why?
|
| Platelet Transfusion | 1 | 2019 | 294 | 0.140 |
Why?
|
| Submandibular Gland | 4 | 1989 | 87 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2018 | 2057 | 0.130 |
Why?
|
| Weight Loss | 2 | 2020 | 2671 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2019 | 2895 | 0.130 |
Why?
|
| Depression | 3 | 2024 | 8057 | 0.130 |
Why?
|
| NF-kappa B | 5 | 2014 | 2472 | 0.130 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.130 |
Why?
|
| Gentamicins | 1 | 2016 | 251 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2009 | 10748 | 0.130 |
Why?
|
| United Nations | 1 | 2016 | 150 | 0.120 |
Why?
|
| History, 20th Century | 2 | 2018 | 2772 | 0.120 |
Why?
|
| Coagulants | 1 | 2015 | 45 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2023 | 1780 | 0.120 |
Why?
|
| Time Factors | 15 | 2017 | 39872 | 0.120 |
Why?
|
| Epigenomics | 1 | 2021 | 936 | 0.120 |
Why?
|
| Tyrphostins | 2 | 2004 | 63 | 0.120 |
Why?
|
| Phosphorylation | 11 | 2016 | 8297 | 0.120 |
Why?
|
| Caspase 3 | 5 | 2011 | 728 | 0.120 |
Why?
|
| Genistein | 2 | 2004 | 86 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 2 | 2011 | 1373 | 0.120 |
Why?
|
| Drug Therapy, Combination | 6 | 2021 | 6293 | 0.120 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2015 | 426 | 0.120 |
Why?
|
| Liver Cirrhosis, Experimental | 1 | 1994 | 29 | 0.120 |
Why?
|
| Aging | 5 | 2021 | 8650 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 1793 | 0.120 |
Why?
|
| Hypertension, Renovascular | 2 | 1993 | 116 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2011 | 3774 | 0.110 |
Why?
|
| Immunohistochemistry | 12 | 2019 | 11070 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 3 | 2010 | 1130 | 0.110 |
Why?
|
| Reperfusion Injury | 3 | 2009 | 1022 | 0.110 |
Why?
|
| RNA Polymerase I | 1 | 2013 | 22 | 0.110 |
Why?
|
| Risk Assessment | 5 | 2019 | 23884 | 0.110 |
Why?
|
| Shigella dysenteriae | 1 | 2013 | 14 | 0.110 |
Why?
|
| Chemoprevention | 1 | 2016 | 326 | 0.110 |
Why?
|
| Mesoderm | 2 | 2007 | 672 | 0.110 |
Why?
|
| Travel | 1 | 2019 | 785 | 0.110 |
Why?
|
| Developed Countries | 1 | 2016 | 440 | 0.110 |
Why?
|
| Caspase 12 | 2 | 2010 | 8 | 0.110 |
Why?
|
| Isoenzymes | 1 | 1998 | 1686 | 0.110 |
Why?
|
| Growth | 2 | 1988 | 365 | 0.110 |
Why?
|
| Periodicals as Topic | 2 | 2019 | 1462 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2009 | 8143 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 13 | 2021 | 22003 | 0.110 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2013 | 136 | 0.100 |
Why?
|
| United States | 12 | 2024 | 72136 | 0.100 |
Why?
|
| Sex Characteristics | 3 | 2019 | 2621 | 0.100 |
Why?
|
| Endothelium, Vascular | 5 | 2007 | 4429 | 0.100 |
Why?
|
| Models, Animal | 1 | 2018 | 2112 | 0.100 |
Why?
|
| Dietary Proteins | 3 | 2002 | 949 | 0.100 |
Why?
|
| Long-Term Care | 2 | 2016 | 631 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2007 | 10416 | 0.100 |
Why?
|
| Pyridines | 6 | 2007 | 2859 | 0.100 |
Why?
|
| Adenoma | 1 | 2002 | 2148 | 0.100 |
Why?
|
| Umbilical Veins | 3 | 2005 | 426 | 0.100 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 1155 | 0.100 |
Why?
|
| Forecasting | 1 | 2021 | 2923 | 0.100 |
Why?
|
| Peptide Fragments | 4 | 2018 | 5098 | 0.090 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 1468 | 0.090 |
Why?
|
| Clinical Trials as Topic | 4 | 2024 | 7985 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2021 | 1150 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2012 | 173 | 0.090 |
Why?
|
| Enalapril | 3 | 2007 | 311 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2016 | 1177 | 0.090 |
Why?
|
| Mice, Knockout | 7 | 2022 | 14354 | 0.090 |
Why?
|
| Foundations | 1 | 2011 | 96 | 0.090 |
Why?
|
| Janus Kinases | 1 | 2012 | 249 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2006 | 4567 | 0.090 |
Why?
|
| Albumins | 3 | 2022 | 575 | 0.090 |
Why?
|
| Primary Health Care | 2 | 2024 | 4652 | 0.090 |
Why?
|
| Blood Platelets | 2 | 2019 | 2475 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2007 | 1136 | 0.090 |
Why?
|
| STAT1 Transcription Factor | 1 | 2012 | 333 | 0.090 |
Why?
|
| Perindopril | 5 | 2011 | 13 | 0.090 |
Why?
|
| Nucleic Acid Hybridization | 4 | 1990 | 1304 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 2 | 1998 | 1185 | 0.090 |
Why?
|
| Morbidity | 1 | 2016 | 1754 | 0.090 |
Why?
|
| Protein Isoforms | 1 | 2015 | 1694 | 0.090 |
Why?
|
| Adiposity | 1 | 2020 | 1858 | 0.090 |
Why?
|
| Caspases | 4 | 2006 | 876 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 1415 | 0.090 |
Why?
|
| Protein Kinase C | 5 | 2006 | 1199 | 0.090 |
Why?
|
| Renal Dialysis | 5 | 2007 | 1786 | 0.090 |
Why?
|
| Hypertonic Solutions | 1 | 2009 | 82 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 5 | 2017 | 1245 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2002 | 2276 | 0.080 |
Why?
|
| Family | 1 | 2020 | 3188 | 0.080 |
Why?
|
| Lactoylglutathione Lyase | 1 | 2009 | 13 | 0.080 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2016 | 1014 | 0.080 |
Why?
|
| Pyruvaldehyde | 1 | 2009 | 16 | 0.080 |
Why?
|
| Food Technology | 1 | 2008 | 6 | 0.080 |
Why?
|
| Transcription, Genetic | 3 | 2017 | 7590 | 0.080 |
Why?
|
| Acute Disease | 6 | 2016 | 7225 | 0.080 |
Why?
|
| Mutation | 5 | 2022 | 29915 | 0.080 |
Why?
|
| Diet | 3 | 2020 | 8005 | 0.080 |
Why?
|
| Sodium, Dietary | 2 | 1989 | 425 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 2115 | 0.080 |
Why?
|
| Chronic Disease | 5 | 2016 | 9267 | 0.080 |
Why?
|
| Kidney Cortex | 2 | 2002 | 169 | 0.080 |
Why?
|
| Transfection | 6 | 2009 | 5779 | 0.080 |
Why?
|
| Enzyme Activators | 1 | 2009 | 57 | 0.080 |
Why?
|
| Foodborne Diseases | 1 | 2008 | 40 | 0.080 |
Why?
|
| Patient Transfer | 1 | 2016 | 777 | 0.080 |
Why?
|
| Acetophenones | 1 | 2008 | 52 | 0.080 |
Why?
|
| Animal Feed | 1 | 2008 | 112 | 0.080 |
Why?
|
| Kidney Medulla | 2 | 2002 | 169 | 0.080 |
Why?
|
| Cell Membrane | 3 | 2015 | 3680 | 0.080 |
Why?
|
| Blotting, Northern | 7 | 2003 | 1543 | 0.080 |
Why?
|
| Hemin | 3 | 2003 | 50 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 4 | 2017 | 609 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2016 | 867 | 0.080 |
Why?
|
| Plastics | 1 | 2008 | 115 | 0.080 |
Why?
|
| Cobalt | 2 | 2005 | 154 | 0.080 |
Why?
|
| Prevalence | 7 | 2024 | 15651 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2023 | 17768 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2017 | 2912 | 0.080 |
Why?
|
| Endocrine System Diseases | 1 | 2010 | 249 | 0.070 |
Why?
|
| Registries | 1 | 2004 | 8175 | 0.070 |
Why?
|
| Rats, Inbred WKY | 6 | 1990 | 151 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2004 | 2470 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 868 | 0.070 |
Why?
|
| Young Adult | 3 | 2022 | 58808 | 0.070 |
Why?
|
| Cell Hypoxia | 5 | 2009 | 655 | 0.070 |
Why?
|
| Hemostasis | 2 | 2000 | 466 | 0.070 |
Why?
|
| Echocardiography | 4 | 2021 | 4962 | 0.070 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2007 | 52 | 0.070 |
Why?
|
| Proteomics | 1 | 2021 | 3816 | 0.070 |
Why?
|
| Genes, myc | 1 | 2008 | 391 | 0.070 |
Why?
|
| Diet, Sodium-Restricted | 3 | 2002 | 291 | 0.070 |
Why?
|
| Watchful Waiting | 1 | 2011 | 509 | 0.070 |
Why?
|
| Blood Coagulation | 1 | 2013 | 1149 | 0.070 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 538 | 0.070 |
Why?
|
| Saphenous Vein | 2 | 2000 | 517 | 0.070 |
Why?
|
| Epoetin Alfa | 1 | 2006 | 78 | 0.070 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 1 | 2006 | 31 | 0.070 |
Why?
|
| Nephritis, Interstitial | 1 | 2007 | 154 | 0.070 |
Why?
|
| Cytoskeleton | 1 | 2011 | 1167 | 0.070 |
Why?
|
| Transplantation, Homologous | 8 | 2005 | 4809 | 0.070 |
Why?
|
| Heat-Shock Proteins | 3 | 2010 | 795 | 0.070 |
Why?
|
| Epithelium | 4 | 2006 | 1605 | 0.070 |
Why?
|
| China | 2 | 2009 | 2333 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2007 | 3480 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2016 | 2560 | 0.060 |
Why?
|
| Serum Albumin, Bovine | 1 | 2006 | 322 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 2307 | 0.060 |
Why?
|
| Thrombosis | 1 | 2019 | 2929 | 0.060 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2005 | 68 | 0.060 |
Why?
|
| Renal Circulation | 2 | 1999 | 291 | 0.060 |
Why?
|
| Drug Synergism | 4 | 2009 | 1745 | 0.060 |
Why?
|
| Succimer | 1 | 1985 | 31 | 0.060 |
Why?
|
| Sodium | 3 | 1990 | 1588 | 0.060 |
Why?
|
| Dairy Products | 1 | 2008 | 491 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 7 | 2017 | 5779 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2021 | 12876 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2015 | 4485 | 0.060 |
Why?
|
| Diet, Protein-Restricted | 1 | 2005 | 73 | 0.060 |
Why?
|
| Growth Substances | 3 | 2002 | 768 | 0.060 |
Why?
|
| Psychotherapy | 2 | 2024 | 1640 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2019 | 6520 | 0.060 |
Why?
|
| Technetium | 1 | 1985 | 321 | 0.060 |
Why?
|
| Glycoproteins | 2 | 2006 | 2205 | 0.060 |
Why?
|
| Onium Compounds | 1 | 2004 | 27 | 0.060 |
Why?
|
| Phenotype | 5 | 2016 | 16534 | 0.060 |
Why?
|
| Transformation, Genetic | 1 | 2004 | 192 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2012 | 1129 | 0.060 |
Why?
|
| Serum Albumin | 1 | 2007 | 673 | 0.060 |
Why?
|
| Feedback, Physiological | 1 | 2007 | 475 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 1444 | 0.060 |
Why?
|
| Anthracenes | 1 | 2004 | 83 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2006 | 477 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2012 | 3156 | 0.060 |
Why?
|
| Thiophenes | 2 | 2022 | 569 | 0.060 |
Why?
|
| Sepsis | 1 | 2018 | 2587 | 0.060 |
Why?
|
| Healthy People Programs | 1 | 2004 | 53 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2018 | 1171 | 0.060 |
Why?
|
| Hypertrophy | 5 | 2004 | 555 | 0.060 |
Why?
|
| RNA, Small Interfering | 4 | 2019 | 3432 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2016 | 3891 | 0.060 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2006 | 397 | 0.060 |
Why?
|
| Hexosamines | 1 | 2003 | 40 | 0.060 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2004 | 105 | 0.060 |
Why?
|
| Plasminogen Activators | 1 | 2003 | 199 | 0.050 |
Why?
|
| Sulfhydryl Compounds | 1 | 1985 | 297 | 0.050 |
Why?
|
| Flavonoids | 2 | 2004 | 443 | 0.050 |
Why?
|
| Response Elements | 2 | 2002 | 308 | 0.050 |
Why?
|
| Protein Biosynthesis | 2 | 2005 | 2105 | 0.050 |
Why?
|
| Civil Rights | 1 | 2024 | 132 | 0.050 |
Why?
|
| Dexamethasone | 2 | 2002 | 1927 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 2005 | 328 | 0.050 |
Why?
|
| Middle Aged | 8 | 2022 | 219568 | 0.050 |
Why?
|
| Calcium Channels, L-Type | 1 | 2004 | 240 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2005 | 532 | 0.050 |
Why?
|
| Prednisone | 5 | 2000 | 1565 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2006 | 349 | 0.050 |
Why?
|
| Ethics Committees, Research | 1 | 2004 | 196 | 0.050 |
Why?
|
| Public Health | 1 | 2016 | 2658 | 0.050 |
Why?
|
| Cathepsin L | 1 | 2022 | 68 | 0.050 |
Why?
|
| Research Design | 1 | 2018 | 6157 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 911 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2004 | 1486 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 1788 | 0.050 |
Why?
|
| Incidence | 2 | 2019 | 21272 | 0.050 |
Why?
|
| Radioimmunoassay | 4 | 2002 | 866 | 0.050 |
Why?
|
| Police | 1 | 2024 | 157 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3196 | 0.050 |
Why?
|
| Sex Chromosomes | 1 | 2002 | 101 | 0.050 |
Why?
|
| Conflict of Interest | 1 | 2007 | 548 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2006 | 719 | 0.050 |
Why?
|
| Microscopy, Electron | 5 | 2005 | 2557 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2005 | 964 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2010 | 1160 | 0.050 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2021 | 45 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2005 | 3090 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2007 | 2020 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2004 | 537 | 0.050 |
Why?
|
| Theophylline | 1 | 2021 | 131 | 0.050 |
Why?
|
| Testosterone | 2 | 1989 | 2471 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 3992 | 0.050 |
Why?
|
| Autophagy | 1 | 2009 | 1322 | 0.050 |
Why?
|
| Testis | 4 | 1993 | 794 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2004 | 551 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1989 | 1972 | 0.050 |
Why?
|
| Chlorambucil | 2 | 1980 | 42 | 0.050 |
Why?
|
| Heart Failure | 5 | 2006 | 11593 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 3 | 2007 | 282 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2024 | 374 | 0.050 |
Why?
|
| Research | 2 | 2005 | 1976 | 0.050 |
Why?
|
| Prisoners | 1 | 2024 | 314 | 0.050 |
Why?
|
| Mitochondria | 2 | 2004 | 3584 | 0.050 |
Why?
|
| Heme | 1 | 2002 | 313 | 0.050 |
Why?
|
| Algorithms | 1 | 2021 | 13961 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 4 | 2006 | 818 | 0.040 |
Why?
|
| Drug Industry | 1 | 2007 | 787 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2003 | 604 | 0.040 |
Why?
|
| Physicians, Women | 1 | 2006 | 495 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 1659 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 2 | 2005 | 2646 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2024 | 672 | 0.040 |
Why?
|
| Adrenal Glands | 3 | 1988 | 554 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2004 | 699 | 0.040 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 9404 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 695 | 0.040 |
Why?
|
| Base Sequence | 6 | 2012 | 12436 | 0.040 |
Why?
|
| Cell Division | 2 | 2004 | 4458 | 0.040 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenases | 1 | 1999 | 5 | 0.040 |
Why?
|
| Carbenoxolone | 1 | 1999 | 8 | 0.040 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 1999 | 29 | 0.040 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2005 | 733 | 0.040 |
Why?
|
| Bile Ducts | 2 | 2006 | 282 | 0.040 |
Why?
|
| Social Justice | 1 | 2024 | 479 | 0.040 |
Why?
|
| Captopril | 3 | 2001 | 265 | 0.040 |
Why?
|
| Renal Plasma Flow, Effective | 1 | 1999 | 4 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 1755 | 0.040 |
Why?
|
| Prednisolone | 1 | 2000 | 326 | 0.040 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2001 | 362 | 0.040 |
Why?
|
| Feedback | 3 | 1999 | 791 | 0.040 |
Why?
|
| Aortic Valve Stenosis | 1 | 1991 | 2002 | 0.040 |
Why?
|
| Sex Factors | 4 | 2019 | 10504 | 0.040 |
Why?
|
| Defective Viruses | 1 | 1999 | 89 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2005 | 1573 | 0.040 |
Why?
|
| Cisplatin | 1 | 2005 | 1645 | 0.040 |
Why?
|
| Plasmids | 1 | 2004 | 2275 | 0.040 |
Why?
|
| Molecular Weight | 3 | 1998 | 2185 | 0.040 |
Why?
|
| Electroconvulsive Therapy | 1 | 2024 | 500 | 0.040 |
Why?
|
| Molecular Chaperones | 2 | 2006 | 752 | 0.040 |
Why?
|
| Complement C4b | 1 | 1999 | 132 | 0.040 |
Why?
|
| Canada | 1 | 2004 | 2111 | 0.040 |
Why?
|
| Hypertension, Portal | 2 | 2006 | 226 | 0.040 |
Why?
|
| Heymann Nephritis Antigenic Complex | 1 | 1998 | 15 | 0.040 |
Why?
|
| LDL-Receptor Related Protein-Associated Protein | 1 | 1998 | 17 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 1332 | 0.040 |
Why?
|
| Corticosterone | 1 | 1999 | 304 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 2 | 2009 | 1477 | 0.040 |
Why?
|
| Aftercare | 1 | 2024 | 910 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 9160 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 5331 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2006 | 1192 | 0.040 |
Why?
|
| Streptozocin | 1 | 2018 | 193 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 769 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 15225 | 0.040 |
Why?
|
| Escherichia coli Infections | 3 | 2019 | 523 | 0.040 |
Why?
|
| Isoproterenol | 1 | 1998 | 394 | 0.040 |
Why?
|
| Antibody Specificity | 2 | 1998 | 1060 | 0.040 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2012 | 294 | 0.040 |
Why?
|
| Endodermal Sinus Tumor | 1 | 1998 | 53 | 0.040 |
Why?
|
| Circadian Rhythm | 2 | 2002 | 2567 | 0.040 |
Why?
|
| Twins, Monozygotic | 1 | 1999 | 469 | 0.040 |
Why?
|
| Peptides | 2 | 2008 | 4341 | 0.040 |
Why?
|
| Politics | 1 | 2003 | 815 | 0.030 |
Why?
|
| Polyarteritis Nodosa | 1 | 1977 | 70 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2006 | 685 | 0.030 |
Why?
|
| Complement Activation | 1 | 1999 | 446 | 0.030 |
Why?
|
| Molecular Sequence Data | 5 | 2006 | 17617 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1999 | 640 | 0.030 |
Why?
|
| Tissue Distribution | 6 | 1994 | 2262 | 0.030 |
Why?
|
| Models, Biological | 3 | 2016 | 9460 | 0.030 |
Why?
|
| Warts | 1 | 1977 | 66 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2016 | 829 | 0.030 |
Why?
|
| Body Weight | 4 | 2015 | 4603 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1998 | 344 | 0.030 |
Why?
|
| Biomedical Research | 2 | 2019 | 3418 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 2003 | 6127 | 0.030 |
Why?
|
| Cysteamine | 1 | 1995 | 24 | 0.030 |
Why?
|
| Solubility | 1 | 1998 | 1088 | 0.030 |
Why?
|
| DNA Primers | 2 | 2004 | 2816 | 0.030 |
Why?
|
| Nitric Oxide | 2 | 1995 | 2131 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2006 | 1930 | 0.030 |
Why?
|
| Fibrin | 2 | 2017 | 505 | 0.030 |
Why?
|
| Immunization | 1 | 2000 | 1227 | 0.030 |
Why?
|
| Calcium | 2 | 2004 | 5721 | 0.030 |
Why?
|
| Weaning | 1 | 2015 | 103 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 2 | 1995 | 906 | 0.030 |
Why?
|
| Receptors, Leptin | 1 | 2017 | 350 | 0.030 |
Why?
|
| Neurofibromatoses | 2 | 2005 | 299 | 0.030 |
Why?
|
| Pterins | 1 | 1995 | 11 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 2416 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2002 | 1474 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 1998 | 485 | 0.030 |
Why?
|
| Aortic Coarctation | 2 | 1991 | 282 | 0.030 |
Why?
|
| Sexual Maturation | 2 | 1988 | 260 | 0.030 |
Why?
|
| GTP Cyclohydrolase | 1 | 1995 | 47 | 0.030 |
Why?
|
| Histological Techniques | 1 | 2015 | 194 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2005 | 3997 | 0.030 |
Why?
|
| Hydralazine | 2 | 2007 | 34 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1993 | 2090 | 0.030 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1995 | 149 | 0.030 |
Why?
|
| Diuresis | 4 | 2009 | 106 | 0.030 |
Why?
|
| Microvilli | 1 | 1995 | 233 | 0.030 |
Why?
|
| Azaserine | 2 | 2004 | 8 | 0.030 |
Why?
|
| Biological Transport | 1 | 1999 | 2084 | 0.030 |
Why?
|
| Anthropometry | 1 | 2019 | 1347 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2001 | 1016 | 0.030 |
Why?
|
| Thiones | 1 | 2014 | 46 | 0.030 |
Why?
|
| Acetylation | 1 | 2017 | 1060 | 0.030 |
Why?
|
| Caspase 9 | 2 | 2005 | 185 | 0.030 |
Why?
|
| Vimentin | 2 | 2005 | 255 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2004 | 4087 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2015 | 296 | 0.030 |
Why?
|
| Streptococcal Infections | 2 | 1977 | 617 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2015 | 677 | 0.030 |
Why?
|
| Temperature | 2 | 2003 | 2219 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1995 | 526 | 0.030 |
Why?
|
| Ligation | 1 | 1994 | 448 | 0.030 |
Why?
|
| Virus Replication | 1 | 2021 | 2430 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1989 | 1975 | 0.030 |
Why?
|
| Iron | 1 | 2002 | 1786 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2019 | 996 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1998 | 2497 | 0.030 |
Why?
|
| Acidosis, Renal Tubular | 1 | 1993 | 50 | 0.030 |
Why?
|
| RNA | 3 | 2005 | 2716 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2002 | 2860 | 0.030 |
Why?
|
| Suicide | 1 | 2024 | 1599 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 1993 | 1900 | 0.030 |
Why?
|
| Environment | 1 | 1999 | 1118 | 0.030 |
Why?
|
| Rats, Inbred SHR | 2 | 1989 | 186 | 0.030 |
Why?
|
| Piperidines | 1 | 2021 | 1639 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 2797 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2015 | 1172 | 0.030 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1995 | 477 | 0.030 |
Why?
|
| Nephrosclerosis | 1 | 2011 | 11 | 0.030 |
Why?
|
| Consensus Sequence | 2 | 2004 | 365 | 0.030 |
Why?
|
| Punctures | 1 | 1993 | 365 | 0.030 |
Why?
|
| Insulin-Secreting Cells | 1 | 2019 | 896 | 0.020 |
Why?
|
| Biphenyl Compounds | 2 | 1994 | 988 | 0.020 |
Why?
|
| Health Behavior | 1 | 2023 | 2617 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1999 | 2194 | 0.020 |
Why?
|
| Life Style | 1 | 2023 | 3886 | 0.020 |
Why?
|
| Factor Xa | 2 | 2005 | 167 | 0.020 |
Why?
|
| RNA Interference | 2 | 2012 | 2836 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 931 | 0.020 |
Why?
|
| Fetal Growth Retardation | 1 | 2015 | 579 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 2005 | 4169 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 1994 | 591 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1998 | 1411 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2011 | 1404 | 0.020 |
Why?
|
| ROC Curve | 1 | 2019 | 3563 | 0.020 |
Why?
|
| beta Catenin | 1 | 2016 | 1043 | 0.020 |
Why?
|
| Renal Artery | 1 | 1993 | 351 | 0.020 |
Why?
|
| Membrane Potentials | 2 | 2005 | 1094 | 0.020 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2014 | 619 | 0.020 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 1991 | 172 | 0.020 |
Why?
|
| Antigens, Viral, Tumor | 1 | 1991 | 153 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 2005 | 10171 | 0.020 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2010 | 103 | 0.020 |
Why?
|
| Renal Artery Obstruction | 1 | 1991 | 219 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1991 | 763 | 0.020 |
Why?
|
| Stress, Physiological | 2 | 2009 | 1398 | 0.020 |
Why?
|
| Genes, Dominant | 2 | 2003 | 862 | 0.020 |
Why?
|
| Antigens | 2 | 1995 | 1445 | 0.020 |
Why?
|
| Transcription Factor CHOP | 1 | 2010 | 67 | 0.020 |
Why?
|
| Loop of Henle | 1 | 2009 | 38 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2004 | 611 | 0.020 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 1990 | 257 | 0.020 |
Why?
|
| Aged | 3 | 2019 | 168218 | 0.020 |
Why?
|
| Chlorpropamide | 1 | 1969 | 6 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2015 | 6234 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2019 | 2612 | 0.020 |
Why?
|
| Mifepristone | 2 | 2002 | 150 | 0.020 |
Why?
|
| Hemodynamics | 4 | 2002 | 4159 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 3609 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2010 | 250 | 0.020 |
Why?
|
| Tunicamycin | 1 | 2009 | 108 | 0.020 |
Why?
|
| Rats, Transgenic | 1 | 2009 | 69 | 0.020 |
Why?
|
| DNA | 4 | 2001 | 7199 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 2006 | 13447 | 0.020 |
Why?
|
| Pregnancy in Diabetics | 1 | 2010 | 194 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 25956 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 3006 | 0.020 |
Why?
|
| Cell Survival | 3 | 2006 | 5781 | 0.020 |
Why?
|
| Vasopressins | 2 | 1971 | 354 | 0.020 |
Why?
|
| Heart | 1 | 2002 | 4382 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 5786 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1989 | 350 | 0.020 |
Why?
|
| Mutagenesis | 1 | 1992 | 1233 | 0.020 |
Why?
|
| Myocardium | 2 | 1994 | 4690 | 0.020 |
Why?
|
| Transgenes | 1 | 2011 | 1007 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1993 | 601 | 0.020 |
Why?
|
| Pyrazines | 1 | 2014 | 1198 | 0.020 |
Why?
|
| Norepinephrine | 2 | 2002 | 897 | 0.020 |
Why?
|
| Glipizide | 1 | 2008 | 48 | 0.020 |
Why?
|
| Macrolides | 1 | 2009 | 205 | 0.020 |
Why?
|
| Osmolar Concentration | 3 | 1995 | 660 | 0.020 |
Why?
|
| Skin Diseases | 1 | 1977 | 1088 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 1989 | 335 | 0.020 |
Why?
|
| Phagosomes | 1 | 2009 | 199 | 0.020 |
Why?
|
| Consensus | 1 | 2017 | 3099 | 0.020 |
Why?
|
| Venoms | 1 | 2008 | 95 | 0.020 |
Why?
|
| Stroke Volume | 2 | 2020 | 5460 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 12096 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 1245 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1999 | 1452 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2019 | 4215 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 695 | 0.020 |
Why?
|
| Blood Vessels | 1 | 1993 | 1112 | 0.020 |
Why?
|
| Kidney Tubules, Distal | 1 | 2006 | 42 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 1751 | 0.020 |
Why?
|
| Antibodies | 2 | 1998 | 2420 | 0.020 |
Why?
|
| Leupeptins | 1 | 2006 | 113 | 0.020 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 1993 | 781 | 0.020 |
Why?
|
| Acrylates | 1 | 2006 | 79 | 0.020 |
Why?
|
| Rats, Inbred BB | 1 | 2006 | 29 | 0.020 |
Why?
|
| Superoxide Dismutase | 2 | 2002 | 593 | 0.020 |
Why?
|
| Vasodilator Agents | 2 | 2002 | 973 | 0.020 |
Why?
|
| Radiography | 2 | 2005 | 6954 | 0.020 |
Why?
|
| Glutathione | 1 | 2009 | 579 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2017 | 2504 | 0.020 |
Why?
|
| Magnesium | 1 | 1989 | 809 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2006 | 189 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2007 | 411 | 0.020 |
Why?
|
| Calpain | 1 | 2006 | 145 | 0.020 |
Why?
|
| Urography | 2 | 1985 | 312 | 0.020 |
Why?
|
| Angiotensins | 1 | 1986 | 143 | 0.020 |
Why?
|
| NADP | 1 | 2006 | 222 | 0.020 |
Why?
|
| Medical History Taking | 1 | 1989 | 772 | 0.020 |
Why?
|
| Chromogenic Compounds | 1 | 2005 | 31 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2006 | 198 | 0.020 |
Why?
|
| Potassium | 1 | 1989 | 1310 | 0.020 |
Why?
|
| Enuresis | 1 | 2005 | 50 | 0.020 |
Why?
|
| Electron Transport Complex I | 1 | 2006 | 152 | 0.020 |
Why?
|
| 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt | 1 | 2004 | 5 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2002 | 3593 | 0.020 |
Why?
|
| Syndrome | 1 | 1991 | 3262 | 0.020 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 1985 | 67 | 0.020 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2005 | 30 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 473 | 0.020 |
Why?
|
| Technetium Tc 99m Dimercaptosuccinic Acid | 1 | 1985 | 81 | 0.020 |
Why?
|
| Antimycin A | 1 | 2004 | 31 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2005 | 6068 | 0.020 |
Why?
|
| Pentetic Acid | 1 | 1985 | 209 | 0.020 |
Why?
|
| Growth Disorders | 1 | 1990 | 653 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 460 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 283 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2005 | 173 | 0.010 |
Why?
|
| Comorbidity | 1 | 2019 | 10495 | 0.010 |
Why?
|
| Antimutagenic Agents | 1 | 2004 | 6 | 0.010 |
Why?
|
| Maleimides | 1 | 2004 | 113 | 0.010 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 2004 | 51 | 0.010 |
Why?
|
| Aminohippuric Acids | 2 | 1974 | 8 | 0.010 |
Why?
|
| Catecholamines | 1 | 2005 | 385 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2006 | 564 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2018 | 4373 | 0.010 |
Why?
|
| Desmin | 1 | 2004 | 99 | 0.010 |
Why?
|
| Career Mobility | 1 | 2006 | 258 | 0.010 |
Why?
|
| Inulin | 2 | 1974 | 68 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1985 | 1628 | 0.010 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2004 | 93 | 0.010 |
Why?
|
| Diazooxonorleucine | 1 | 2003 | 7 | 0.010 |
Why?
|
| Histocompatibility Testing | 2 | 1982 | 717 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2004 | 460 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 1074 | 0.010 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2003 | 45 | 0.010 |
Why?
|
| Water | 2 | 1971 | 1402 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 2005 | 437 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2002 | 3733 | 0.010 |
Why?
|
| Glucosamine | 1 | 2003 | 128 | 0.010 |
Why?
|
| MafG Transcription Factor | 1 | 2002 | 7 | 0.010 |
Why?
|
| Boston | 2 | 1991 | 9304 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2002 | 221 | 0.010 |
Why?
|
| Kinetics | 3 | 2002 | 6371 | 0.010 |
Why?
|
| Inflammation | 2 | 2002 | 10718 | 0.010 |
Why?
|
| Nephrosis, Lipoid | 1 | 1983 | 45 | 0.010 |
Why?
|
| Hydrostatic Pressure | 1 | 2003 | 95 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 2003 | 102 | 0.010 |
Why?
|
| Cadaver | 3 | 1982 | 1345 | 0.010 |
Why?
|
| Cell Movement | 2 | 2005 | 5201 | 0.010 |
Why?
|
| Cyclic AMP | 2 | 1981 | 1455 | 0.010 |
Why?
|
| Calcium Channels | 1 | 2006 | 618 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1986 | 959 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2006 | 1991 | 0.010 |
Why?
|
| Somatomedins | 1 | 2003 | 178 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 2057 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2018 | 3783 | 0.010 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3076 | 0.010 |
Why?
|
| Capillaries | 1 | 2005 | 744 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1987 | 1516 | 0.010 |
Why?
|
| Natriuresis | 2 | 1992 | 105 | 0.010 |
Why?
|
| Heart Rate | 3 | 2002 | 4166 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 13591 | 0.010 |
Why?
|
| Acetylglucosaminidase | 1 | 2002 | 66 | 0.010 |
Why?
|
| Crystallins | 1 | 2002 | 75 | 0.010 |
Why?
|
| Mannitol | 2 | 2000 | 180 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 2005 | 769 | 0.010 |
Why?
|
| Amoxicillin | 1 | 1983 | 180 | 0.010 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2002 | 66 | 0.010 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2002 | 107 | 0.010 |
Why?
|
| Genes | 1 | 1986 | 1845 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 319 | 0.010 |
Why?
|
| Cattle | 1 | 2007 | 3845 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 1989 | 2676 | 0.010 |
Why?
|
| Collagen Type IV | 1 | 2002 | 127 | 0.010 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2001 | 78 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 530 | 0.010 |
Why?
|
| Fibronectins | 1 | 2005 | 722 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2006 | 2284 | 0.010 |
Why?
|
| Chromatography, Gel | 3 | 1979 | 645 | 0.010 |
Why?
|
| Sorbitol | 1 | 2000 | 56 | 0.010 |
Why?
|
| Point Mutation | 1 | 2006 | 1593 | 0.010 |
Why?
|
| Cell Death | 1 | 2006 | 1668 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2002 | 295 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2006 | 1185 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 490 | 0.010 |
Why?
|
| Particle Size | 1 | 2005 | 1641 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 459 | 0.010 |
Why?
|
| ADAM Proteins | 1 | 2002 | 238 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2004 | 616 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2002 | 393 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2005 | 1553 | 0.010 |
Why?
|
| Nephritis | 1 | 1981 | 147 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 1647 | 0.010 |
Why?
|
| Microcirculation | 1 | 2005 | 1273 | 0.010 |
Why?
|
| Peritonitis | 1 | 1982 | 369 | 0.010 |
Why?
|
| Metformin | 1 | 2008 | 907 | 0.010 |
Why?
|
| Deoxyglucose | 1 | 2000 | 333 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8611 | 0.010 |
Why?
|
| Factor VII | 1 | 2000 | 139 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2005 | 1016 | 0.010 |
Why?
|
| Urothelium | 1 | 2002 | 277 | 0.010 |
Why?
|
| Protoporphyrins | 1 | 2000 | 165 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 2753 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 2176 | 0.010 |
Why?
|
| Graft Survival | 3 | 2006 | 3794 | 0.010 |
Why?
|
| Cell Separation | 1 | 2005 | 1720 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2017 | 22029 | 0.010 |
Why?
|
| Anticholesteremic Agents | 1 | 2006 | 963 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 1982 | 1557 | 0.010 |
Why?
|
| Complement C3b | 1 | 1999 | 99 | 0.010 |
Why?
|
| Aldehyde Reductase | 1 | 1999 | 71 | 0.010 |
Why?
|
| Ferritins | 1 | 2002 | 597 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2002 | 728 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1982 | 1351 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1994 | 14641 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1998 | 110 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1998 | 304 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 2413 | 0.010 |
Why?
|
| Complement C4 | 1 | 1999 | 244 | 0.010 |
Why?
|
| Edema | 2 | 1980 | 768 | 0.010 |
Why?
|
| Endopeptidases | 1 | 2002 | 772 | 0.010 |
Why?
|
| Naphthalenes | 1 | 1999 | 198 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1999 | 613 | 0.010 |
Why?
|
| Androstadienes | 1 | 1999 | 348 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2001 | 1693 | 0.010 |
Why?
|
| Urethral Stricture | 1 | 1977 | 51 | 0.010 |
Why?
|
| Cryoglobulins | 1 | 1977 | 58 | 0.010 |
Why?
|
| Hormone Antagonists | 1 | 1998 | 108 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 2189 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1985 | 1263 | 0.010 |
Why?
|
| Lipopolysaccharides | 2 | 1995 | 2204 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 855 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 2002 | 1066 | 0.010 |
Why?
|
| Headache | 1 | 2005 | 1248 | 0.010 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1977 | 133 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 2825 | 0.010 |
Why?
|
| Recurrence | 2 | 1981 | 8426 | 0.010 |
Why?
|
| Indoles | 1 | 2004 | 1828 | 0.010 |
Why?
|
| Actins | 1 | 2004 | 2049 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2000 | 1249 | 0.010 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1977 | 183 | 0.010 |
Why?
|
| Hydronephrosis | 1 | 1977 | 271 | 0.010 |
Why?
|
| Dogs | 1 | 1981 | 3840 | 0.010 |
Why?
|
| Propranolol | 1 | 1998 | 489 | 0.010 |
Why?
|
| Human Growth Hormone | 1 | 2001 | 638 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1976 | 384 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 1989 | 3242 | 0.010 |
Why?
|
| Nystatin | 1 | 1995 | 22 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2001 | 3069 | 0.010 |
Why?
|
| Nitroarginine | 1 | 1995 | 66 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2004 | 11471 | 0.010 |
Why?
|
| Liver | 2 | 1992 | 7502 | 0.010 |
Why?
|
| Complement C3 | 1 | 1977 | 451 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 1976 | 270 | 0.010 |
Why?
|
| Hypoxanthines | 1 | 1995 | 35 | 0.010 |
Why?
|
| Thionucleotides | 1 | 1995 | 112 | 0.010 |
Why?
|
| Cystine | 1 | 1995 | 94 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1976 | 638 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2019 | 54137 | 0.010 |
Why?
|
| Povidone | 1 | 1974 | 30 | 0.010 |
Why?
|
| Immunologic Techniques | 2 | 1989 | 213 | 0.010 |
Why?
|
| Pteridines | 1 | 1995 | 47 | 0.010 |
Why?
|
| Homeostasis | 1 | 2006 | 3301 | 0.010 |
Why?
|
| Streptococcus pyogenes | 1 | 1977 | 294 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 5484 | 0.010 |
Why?
|
| Sulfides | 1 | 1995 | 170 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1995 | 451 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 1829 | 0.010 |
Why?
|
| Ultrasonography | 2 | 2005 | 5952 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 1995 | 395 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1977 | 979 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1974 | 348 | 0.010 |
Why?
|
| Gastrointestinal Motility | 1 | 1995 | 234 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 1970 | 4673 | 0.010 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1995 | 239 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 1378 | 0.010 |
Why?
|
| Postoperative Complications | 3 | 1981 | 15637 | 0.010 |
Why?
|
| Biochemical Phenomena | 1 | 1993 | 58 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 8553 | 0.010 |
Why?
|
| Permeability | 1 | 1974 | 718 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 2800 | 0.010 |
Why?
|
| Biopsy | 2 | 1977 | 6768 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1974 | 1433 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2002 | 5864 | 0.010 |
Why?
|
| Biochemistry | 1 | 1993 | 114 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 1993 | 11424 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1998 | 1240 | 0.010 |
Why?
|
| Interferons | 1 | 1995 | 705 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2002 | 2980 | 0.010 |
Why?
|
| Rabbits | 1 | 1998 | 4772 | 0.010 |
Why?
|
| Retrospective Studies | 5 | 2001 | 80168 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 1976 | 772 | 0.010 |
Why?
|
| Arginine | 1 | 1995 | 933 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 3442 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1974 | 1032 | 0.010 |
Why?
|
| North America | 1 | 1994 | 1276 | 0.010 |
Why?
|
| Wound Healing | 1 | 2002 | 2783 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 1990 | 174 | 0.010 |
Why?
|
| Dihydrotachysterol | 1 | 1990 | 4 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 1993 | 626 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 1990 | 455 | 0.010 |
Why?
|
| Cyanosis | 1 | 1970 | 86 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2005 | 36284 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 12951 | 0.010 |
Why?
|
| Anura | 1 | 1969 | 80 | 0.010 |
Why?
|
| Receptors, Drug | 1 | 1969 | 157 | 0.010 |
Why?
|
| Electrolytes | 1 | 1989 | 274 | 0.000 |
Why?
|
| Calcitriol | 1 | 1990 | 297 | 0.000 |
Why?
|
| Hematocrit | 1 | 1989 | 627 | 0.000 |
Why?
|
| Methotrexate | 1 | 1995 | 1719 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 2210 | 0.000 |
Why?
|
| Leukocytes | 1 | 1995 | 2025 | 0.000 |
Why?
|
| Catheterization | 1 | 1993 | 1426 | 0.000 |
Why?
|
| Treatment Outcome | 2 | 2006 | 64378 | 0.000 |
Why?
|
| Orchiectomy | 1 | 1989 | 470 | 0.000 |
Why?
|
| Bacteria | 1 | 1998 | 2197 | 0.000 |
Why?
|
| Interview, Psychological | 1 | 1989 | 809 | 0.000 |
Why?
|
| Binding Sites | 1 | 1994 | 6036 | 0.000 |
Why?
|
| Pedigree | 1 | 1993 | 4578 | 0.000 |
Why?
|
| Multicenter Studies as Topic | 1 | 1990 | 1705 | 0.000 |
Why?
|
| Mice, Nude | 1 | 1990 | 3602 | 0.000 |
Why?
|
| Antibody-Coated Bacteria Test, Urinary | 1 | 1983 | 6 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 15785 | 0.000 |
Why?
|
| Hemorrhage | 1 | 1995 | 3400 | 0.000 |
Why?
|
| Actuarial Analysis | 1 | 1982 | 374 | 0.000 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1982 | 516 | 0.000 |
Why?
|
| Cystic Fibrosis | 1 | 1971 | 1274 | 0.000 |
Why?
|
| Species Specificity | 1 | 1986 | 2417 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1991 | 1494 | 0.000 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1990 | 2825 | 0.000 |
Why?
|
| Risk | 2 | 1983 | 9599 | 0.000 |
Why?
|
| Electrophoresis | 1 | 1979 | 234 | 0.000 |
Why?
|
| Follow-Up Studies | 2 | 1980 | 39059 | 0.000 |
Why?
|
| Attention | 1 | 1989 | 2387 | 0.000 |
Why?
|
| Random Allocation | 1 | 1983 | 2385 | 0.000 |
Why?
|
| Brain | 1 | 2005 | 26947 | 0.000 |
Why?
|
| Hepatomegaly | 1 | 1977 | 84 | 0.000 |
Why?
|
| Pneumococcal Infections | 1 | 1982 | 503 | 0.000 |
Why?
|
| Antilymphocyte Serum | 1 | 1978 | 482 | 0.000 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1976 | 187 | 0.000 |
Why?
|
| Appendicitis | 1 | 1982 | 674 | 0.000 |
Why?
|
| Heart Ventricles | 1 | 1987 | 3806 | 0.000 |
Why?
|
| Fibrinolysis | 1 | 1976 | 332 | 0.000 |
Why?
|
| Parathyroid Hormone | 1 | 1981 | 1797 | 0.000 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1976 | 418 | 0.000 |
Why?
|
| Blood Coagulation Factors | 1 | 1976 | 365 | 0.000 |
Why?
|
| Lung | 1 | 1993 | 9985 | 0.000 |
Why?
|
| Blood Proteins | 1 | 1979 | 1173 | 0.000 |
Why?
|
| Kidney Neoplasms | 1 | 1990 | 4312 | 0.000 |
Why?
|
| Fibrinogen | 1 | 1976 | 883 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1990 | 10146 | 0.000 |
Why?
|
| Blood Urea Nitrogen | 1 | 1972 | 186 | 0.000 |
Why?
|
| Methods | 1 | 1972 | 1074 | 0.000 |
Why?
|
| Urinary Catheterization | 1 | 1972 | 198 | 0.000 |
Why?
|
| Kidney Concentrating Ability | 1 | 1971 | 34 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1982 | 5490 | 0.000 |
Why?
|
| Extracellular Space | 1 | 1972 | 564 | 0.000 |
Why?
|
| Water-Electrolyte Balance | 1 | 1971 | 325 | 0.000 |
Why?
|
| Triglycerides | 1 | 1976 | 2451 | 0.000 |
Why?
|
| Cholesterol | 1 | 1976 | 2902 | 0.000 |
Why?
|
| Parents | 1 | 1977 | 3548 | 0.000 |
Why?
|